文献速递鼻科

可降解鼻窦支架局部递送环丙沙星与依伐卡托治疗兔铜绿假单胞菌鼻窦炎

Controlled delivery of ciprofloxacin and ivacaftor via sinus stent in a preclinical model of Pseudomonas sinusitis.
PubMed 文献 · Int Forum Allergy Rhinol · 2019-12-23

该临床前研究在兔铜绿假单胞菌鼻窦炎模型中评估可降解鼻窦支架(CISS)局部递送环丙沙星与依伐卡托的疗效。CISS组较裸支架对照组在CT评分、鼻内镜评分、细菌载量及氯离子转运功能上均显著改善,黏膜与黏膜下组织学亦明显好转。结果表明CISS对铜绿假单胞菌鼻窦炎具有稳健的临床疗效。

要点

  • CISS在兔模型中显著降低CT与鼻内镜评分,改善黏膜炎症。
  • CISS实现约2-log的铜绿假单胞菌载量下降。
  • CISS组氯离子转运显著增加,提示黏液纤毛功能改善。

核心结论

  • CISS在兔铜绿假单胞菌鼻窦炎模型中表现出稳健的临床疗效。
  • 可降解支架双层药物涂层设计可能优于现有铜绿假单胞菌鼻窦炎治疗策略。

研究设计与样本

  • 研究为兔铜绿假单胞菌(PAO1株)鼻窦炎临床前模型。
  • 共置入10个鼻窦支架,其中5个为裸PLLA支架对照,5个为CISS。
  • 感染诱导1周后经背侧鼻窦切开术单侧置入支架,3周后评估。

主要发现

  • CT Kerschner评分变化:对照组0.55±0.92,CISS组-5.92±1.69,p=0.024。
  • 鼻内镜评分:对照组4.0±0.0,CISS组1.875±0.74,p=0.003。
  • PAO1细菌载量变化:对照组-2.14±0.77,CISS组1.84±1.52,p=0.047。
  • 无氯+佛司可林条件下ΔPD:对照组-4.23±1.04 mV,CISS组-18.36±6.31 mV,p=0.026。
  • 治疗组黏膜与黏膜下组织学明显改善。

临床怎么用

  • CISS可能为铜绿假单胞菌鼻窦炎提供局部高浓度、持续递药的治疗选择。
  • 需进一步临床研究验证其在慢性鼻窦炎患者中的疗效与安全性。

局限性

  • 研究为兔临床前模型,样本量小(共10个支架),结论外推至人类需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pseudomonas aeruginosa is common in chronic rhinosinusitus (CRS) and frequently resistant to antibiotic treatment. We recently described the ciprofloxacin and ivacaftor-releasing biodegradable sinus stent (CISS)-a drug-delivery system that administers ciprofloxacin and the mucociliary activator (ivacaftor) at high local concentrations with prolonged mucosal contact time and sustained delivery. The objective of this study is to evaluate the efficacy of the CISS in a rabbit model of P aeruginosa (PAO1 strain) sinusitis. METHODS: Ciprofloxacin/ivacaftor (double layer) was coated on biodegradable poly-D/L-lactic acid (PLLA). A total of 10 sinus stents (5 bare PLLA stent controls, 5 CISSs) were placed unilaterally in rabbit maxillary sinuses via dorsal sinusotomy after inducing infection for 1 week with PAO1. Animals were assessed 3 weeks after stent insertion with sinus culture, nasal endoscopy, computed tomography scan, histopathology, and in-vivo sinus potential difference (SPD) assay. RESULTS: Rabbits treated with CISS had significant reductions in computed tomography (∆ Kerschner scale: control, 0.55 ± 0.92; CISS, -5.92 ± 1.69; p = 0.024) and endoscopy (control, 4.0 ± 0.0; CISS, 1.875 ± 0.74; p = 0.003) scores. A 2-log reduction of PAO1 was observed (control, -2.14 ± 0.77; CISS, 1.84 ± 1.52; p = 0.047). SPD revealed significantly increased Cl- transport in the CISS group compared with the control group (Cl- -free + forskolin ΔPD: control, -4.23 ± 1.04 mV; CISS, -18.36 ± 6.31 mV; p = 0.026). Finally, marked improvements were noted in the histology of the mucosa and submucosa in treated animals. CONCLUSION: The CISS had robust clinical efficacy in treating P aeruginosa rabbit sinusitis. The innovative design of double-layered drug coating on the surface of the biodegradable stent may provide therapeutic advantages over current treatment strategies for P aeruginosa sinusitis.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Lim DJ, McCormick J, Skinner D, et al. Controlled delivery of ciprofloxacin and ivacaftor via sinus stent in a preclinical model of Pseudomonas sinusitis. Int Forum Allergy Rhinol. 2019. PMID: 31872532. doi:10.1002/alr.22514

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。